Anandamide (AEA), initially considered an endocannabinoid, has recently been described as a vanilloid agonist capable of modulating acute pain in brain regions such as the periaqueductal gray (PAG). In this context, AEA role in pain management is complex, since TRPV1 (transient receptor potential vanilloid type 1) and CB1 (cannabinoid receptors type 1) stimulation led to paradoxical effects on nociception. Moreover, acute stress, such as the social defeat, releases this compound into the PAG, making relevant its implication in the stress-induced antinociception phenomenon. Finally, the phosphorylation status of TRPV1 influences its sensitivity to AEA, which is a possible mechanism responsible for the potency and/or time length of AEA-depend...
N-acylethanolamines (NAEs) belong to a growing family of endogenous signalling molecules acting on a...
Modulation of synaptic transmission in the spinal cord dorsal horn plays an important role in develo...
An attractive alternative to the use of direct agonists at the cannabinoid receptor type 1 (CB1) in ...
Transient receptor potential ion channel, vanilloid subfamily, type 1 (TRPV1) cation channel, and ca...
Background and Purpose Endocannabinoids play an important role in modulati ng spinal nociceptive sig...
Introduction: Nucleus cuneiformis (NCF), as part of descending pain inhibitory system, cooperates wi...
Neuropathic pain elevates spinal anandamide (AEA) levels in a way further increased when URB597, an ...
Neuropathic pain elevates spinal anandamide (AEA) levels in a way further increased when URB597, an ...
The neural substrates and mechanisms mediating the antinociceptive effects of the endogenous bioacti...
Inhibitors of fatty acid amide hydrolase (FAAH) and anandamide (AEA) uptake, which limit the degrada...
Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the e...
The endogenous ligand N-arachydonoylethanolamine (anandamide) is an important modulator of nocicept...
In the ventrolateral periaqueductal gray (PAG), activation of excitatory output neurons projecting m...
Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the e...
The endocannabinoid (EC) system consists of two main receptors: cannabinoid type 1 receptor cannabin...
N-acylethanolamines (NAEs) belong to a growing family of endogenous signalling molecules acting on a...
Modulation of synaptic transmission in the spinal cord dorsal horn plays an important role in develo...
An attractive alternative to the use of direct agonists at the cannabinoid receptor type 1 (CB1) in ...
Transient receptor potential ion channel, vanilloid subfamily, type 1 (TRPV1) cation channel, and ca...
Background and Purpose Endocannabinoids play an important role in modulati ng spinal nociceptive sig...
Introduction: Nucleus cuneiformis (NCF), as part of descending pain inhibitory system, cooperates wi...
Neuropathic pain elevates spinal anandamide (AEA) levels in a way further increased when URB597, an ...
Neuropathic pain elevates spinal anandamide (AEA) levels in a way further increased when URB597, an ...
The neural substrates and mechanisms mediating the antinociceptive effects of the endogenous bioacti...
Inhibitors of fatty acid amide hydrolase (FAAH) and anandamide (AEA) uptake, which limit the degrada...
Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the e...
The endogenous ligand N-arachydonoylethanolamine (anandamide) is an important modulator of nocicept...
In the ventrolateral periaqueductal gray (PAG), activation of excitatory output neurons projecting m...
Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the e...
The endocannabinoid (EC) system consists of two main receptors: cannabinoid type 1 receptor cannabin...
N-acylethanolamines (NAEs) belong to a growing family of endogenous signalling molecules acting on a...
Modulation of synaptic transmission in the spinal cord dorsal horn plays an important role in develo...
An attractive alternative to the use of direct agonists at the cannabinoid receptor type 1 (CB1) in ...